Ibrance Illustrates Heavy FDA Workload For 'Breakthrough' Reviews

Approval of Pfizer's breast cancer therapy palbociclib on the basis of Phase II data required an exhaustive set of statistical sensitivity analyses and a striking number of pre-NDA meetings.